US-based biopharmaceutical company Xcovery has begun the Phase III eXalt3 trial of X-396 to treat anaplastic lymphoma kinase (ALK) positive, non-small cell lung cancer (NSCLC).
X-396 is a small molecule, which acts as an inhibitor of anaplastic lymphoma kinase (ALK).
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The open-label, randomised Phase III eXalt3 trial is designed to evaluate the efficacy and safety of X-396 against crizotinib.
The trial has involved more than 400 patients afflicted with ALK+ NSCLC and had a prior treatment history with one chemotherapy regimen and no prior ALK tyrosine kinase inhibitor (TKI) treatments.
Xcovery president and CEO Michael Webb said: "The initiation of our Phase 3 eXalt3 trial represents an important step forward in Xcovery’s advancement of our lead candidate, X-396.
"The recently released data from our ongoing Phase I/II study of X-396 showed promising activity with durable responses noted in both treatment-naïve patients, as well as in patients resistant to current standard-of-care.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalData"These results, coupled with a favourable tolerability profile, support the continued development of X-396 as a potential new treatment option for patients with ALK+ NSCLC. Xcovery will now focus on actively recruiting additional patients and new clinical sites across the globe."
The trial primarily focuses on determining the progression-free survival (PFS) as assessed by an independent radiology review based on RECIST v. 1.1 criteria.
The study additionally intends to evaluate the pharmacokinetic profile of X-396 on selected patients, while samples for exploratory biomarkers research will be compared against the clinical outcomes.
